The Preferential Homing of a Platelet Derived Growth Factor Receptor-recognizing Macromolecule to Fibroblast-like Cells in Fibrotic Tissue
Overview
Pharmacology
Affiliations
Platelet derived growth factor (PDGF) is a key factor in the induction and progression of fibrotic diseases with the activated fibroblast as its target cell. Drug targeting to the PDGF-receptor is explored as a new approach to treat this disease. Therefore, we constructed a macromolecule with affinity for the PDGF-beta receptor by modification of albumin with a small peptide that recognises this PDGF-beta receptor. The binding of the peptide-modified albumin (pPB-HSA) to the PDGF-beta receptor was confirmed in competition studies with PDGF-BB using NIH/3T3-fibroblasts and activated hepatic stellate cells. Furthermore, pPB-HSA was able to reduce PDGF-BB-induced fibroblast proliferation in vitro, and proved to be devoid of proliferation-inducing activity itself. We assessed the distribution of pPB-HSA in vivo in two models of fibrosis and related the distribution of pPB-HSA to PDGF-beta receptor density. In rats with liver fibrosis (bile duct ligation model), pPB-HSA quickly accumulated in the liver in contrast to unmodified HSA (P<0.001). The major part of pPB-HSA in the fibrotic liver was localized in hepatic stellate cells. In rats with renal fibrosis (anti-Thy1.1 model), pPB-HSA also homed to the cells that expressed the PDGF-beta receptor, i.e. the mesangial cells in the glomeruli of the kidney. These results indicate that pPB-HSA may be applied as a macromolecular drug-carrier that accumulates specifically in cells expressing the PDGF-beta receptor, thus allowing a selective delivery of anti-fibrotic agents to these cells.
Li Z, Yang H, Li X, She T, Tao Z, Zhong Y Eur J Nucl Med Mol Imaging. 2024; 51(6):1530-1543.
PMID: 38189910 DOI: 10.1007/s00259-023-06577-7.
Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions.
Eriksson O, Velikyan I Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004406 PMC: 10674214. DOI: 10.3390/ph16111540.
Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications.
Kaps L, Limeres M, Schneider P, Svensson M, Zeyn Y, Fraude S Int J Mol Sci. 2023; 24(14).
PMID: 37511628 PMC: 10380755. DOI: 10.3390/ijms241411869.
Hepatic Stellate Cell Targeting Using Peptide-Modified Biologicals.
Bansal R, Poelstra K Methods Mol Biol. 2023; 2669:269-284.
PMID: 37247067 DOI: 10.1007/978-1-0716-3207-9_17.
Ayazi M, Zivkovic S, Hammel G, Stefanovic B, Ren Y Cells. 2022; 11(15).
PMID: 35954214 PMC: 9367779. DOI: 10.3390/cells11152371.